Better and iQHealthTech join forces to enhance systemic anti-cancer therapy prescription safety

Better and iQHealthTech have formed a development partnership aimed at improving the safety of systemic anti-cancer therapy (SACT) prescribing. Through their collaboration, users of iQHealthTech's iQemo solution will now have access to Better's award-winning ePMA solution, Better Meds, allowing them to manage an ever-increasing number of patients on complex SACT pathways with greater ease and safety.

To achieve this goal, iQHealthTech has committed to adopting openEHR storage standards for key clinical data items. Together, Better and iQHealthTech are poised to transform the way healthcare providers manage systemic anti-cancer therapy, delivering better outcomes for patients and healthcare professionals alike. 

Doug Baker, co-founder and Business Development Director at iQHealth Tech said: “At iQ HealthTech, we recognise that providing the right data in the right place at the right time is critical for empowering clinicians to make the most appropriate clinical decisions to support best patient outcomes. Innovation through open data standards and integration is key to ensuring we deliver on this promise. Providing a more connected, best-of-breed patient health record offers safer management of patients on complex inpatient SACT treatment by providing specialist functionality combined with wider visibility of critical data in one place. We are pleased to announce our collaboration with Better and look forward to working with them to deliver the best possible outcomes for our users and their patients.” 

As it was recently announced, it is possible that the first go-live of this partnership will be seen at The Christie NHS Foundation Trust, which recently selected Better Meds for its new ePMA solution. 

“At Better we believe no single system is able to deal with the emerging challenges of complex treatments in all care settings. We address this with an open-data model that facilitates sharing of information. Collaboration and trust between different providers are essential for establishing connected, best-of-breed solutions which will enable faster innovation in specialist segments like SACT treatment. I firmly believe this aim is reflected in our partnership with iQ HealthTech, which is why we are looking forward to our first joint implementation at The Christie NHS Foundation Trust,” said Roko Malkoč, Better Meds Business Unit Director. 

iQ HealthTech was founded in 2011 with the purpose of developing user-centric technology that improves cancer patient healthcare outcomes, everywhere. iQ HealthTech developed iQemo, the first cloud based SACT EPMA solution. iQemo has been designed collaboratively with many end users and is known for its simple, intuitive user interface and innovative functionality, which has allowed it to gain rapid traction across the UK in both NHS and private hospitals and more recently in Australia.